Press Releases

Press Releases

Date Title & Summary Additional Formats
05/10/17
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
SAN DIEGO , May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and
04/25/17
Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison , M.D., M.P.H., has been named chief medical officer (CMO) of the company. Dr.
04/17/17
Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its Cloudbreak TM antibacterial
03/30/17
Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
CARB-X Funding to Advance Novel First-in-Class Bispecific Immunotherapy to Fight Multi-drug Resistant Bacterial Infections SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
03/29/17
Cidara Therapeutics to Host Investor Day on April 6, 2017
SAN DIEGO , March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017 , from 8:30 a.m. to 11:30 a.m. EDT ( 5:30 a.m. to 8:30 a.m.
03/15/17
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO , March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its
02/21/17
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO , Feb.
01/04/17
Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
Topline Data Expected in First Quarter 2017 SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2
12/14/16
Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
Data Showcase Compound’s Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO --(BUSINESS WIRE)--Dec. 14, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including
11/28/16
Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
SAN DIEGO --(BUSINESS WIRE)--Nov. 28, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be